What is Wegovy?
An introduction to Wegovy, the brand name for semaglutide approved for weight management.
Last updated: January 28, 2026
What is Wegovy?
Wegovy is a brand name for semaglutide, a medication FDA-approved for chronic weight management. It’s the same active ingredient as Ozempic but at a higher dose and approved specifically for obesity and overweight.
How is Wegovy Different from Ozempic?
Both medications contain semaglutide, but they differ in approved use and dosing:
| Feature | Wegovy | Ozempic |
|---|---|---|
| Approved For | Weight management | Type 2 diabetes |
| Maximum Dose | 2.4 mg weekly | 2 mg weekly |
| FDA Approval | June 2021 | December 2017 |
How Does Wegovy Work?
Wegovy works by mimicking GLP-1, a hormone that affects appetite and food intake:
- Reduces hunger signals in the brain
- Increases feelings of fullness after eating
- Slows stomach emptying so you feel satisfied longer
- Improves blood sugar control as a secondary effect
Who is Wegovy Approved For?
FDA-Approved Indications
Adults with:
- Obesity (BMI of 30 or higher), OR
- Overweight (BMI of 27 or higher) with at least one weight-related condition (high blood pressure, type 2 diabetes, high cholesterol)
Also approved for:
- Cardiovascular risk reduction in adults with obesity and established cardiovascular disease
Pediatric Use
Approved for adolescents aged 12 and older with obesity.
What Does the Research Show?
Clinical trials (STEP program) demonstrated significant weight loss:
| Trial | Population | Weight Loss (2.4 mg) |
|---|---|---|
| STEP 1 | Obesity, no diabetes | 14.9% vs 2.4% placebo |
| STEP 2 | Obesity with diabetes | 9.6% vs 3.4% placebo |
| STEP 3 | With intensive behavioral therapy | 16.0% vs 5.7% placebo |
Key Facts
| Fact | Detail |
|---|---|
| Dosing | Once weekly injection |
| Titration Period | 16-20 weeks to reach maintenance dose |
| Administration | Subcutaneous (abdomen, thigh, or upper arm) |
Common Side Effects
- Nausea (typically improves over time)
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Important Considerations
Wegovy carries a boxed warning about thyroid C-cell tumors observed in rodents. It should not be used by people with:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
This guide is for educational purposes only. Wegovy is a prescription medication requiring medical supervision.
Related Content
5-Amino-1MQ
Metabolic · low evidence
Amycretin
Metabolic · moderate evidence
AOD-9604
Metabolic · low evidence
What is Ozempic?
An introduction to Ozempic, the brand name for semaglutide a...
What is Rybelsus?
An introduction to Rybelsus, the oral tablet form of semaglu...
5-Amino-1MQ vs Semaglutide
View side-by-side analysis
Amycretin vs Semaglutide
View side-by-side analysis
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. No spam, just evidence.
No spam. Unsubscribe anytime.
Disclaimer: This educational guide does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.